NCT03369821 - EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study) | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions

Type1 Diabetes Mellitus

Interventions

DIAGNOSTIC_TEST

Beta Cell Loss and Immune Function

Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.

OTHER

Immune Function with RNAseq

Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).

Trial Locations (4)

NOT_YET_RECRUITING

Benaroya Research Institute, Seattle

NOT_YET_RECRUITING

Leiden University Medical Center, Leiden

RECRUITING

Royal Devon & Exeter NHS Foundation Trust, Exeter

ACTIVE_NOT_RECRUITING

King's College London, London